evidence/gaps
Cochrane · systematic review · CD009585

Addition of anti‐leukotriene agents to inhaled corticosteroids in children with persistent asthma

Chauhan, BF, Ben Salah, R, Ducharme, FM · Cochrane Database of Systematic Reviews · 2013 · Cochrane Library

AirwaysAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
5
current version
GRADE rated
5
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 1 · 20%Low 4 · 80%Moderate 0 · 0%High 0 · 0%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Questions and results

Anti‐leukotrienes & ICS versus same dose ICS for asthma

Population: Children with asthma
3 questions
OutcomeEffectEvidenceStatus / GRADE
Participants with one or more exacerbations requiring oral corticosteroids
Anti‐leukotrienes & ICS vs same dose ICS
Risk Ratio 0.81 study · 279 participantsLow
Downgraded: imprecision
Participants with exacerbations requiring hospital admission
Anti‐leukotrienes & ICS vs same dose ICS
no estimate extracted1 study · 279 participantsVery low
Downgraded: imprecision
Change from baseline FEV₁ (%)
Anti‐leukotrienes & ICS vs same dose ICS
no estimate extracted1 study · 279 participantsLow
Downgraded: imprecision

Anti‐leukotrienes & ICS versus higher dose ICS for asthma

Population: Children with asthma
2 questions
OutcomeEffectEvidenceStatus / GRADE
Participants with one or more exacerbations requiring oral corticosteroids
Anti‐leukotrienes & ICS vs higher dose ICS
Risk Ratio 0.821 study · 182 participantsLow
Downgraded: imprecision
Participants with exacerbations requiring hospital admission
Anti‐leukotrienes & ICS vs higher dose ICS
Risk Ratio 11 study · 182 participantsLow
Downgraded: imprecision